Tag: Health Care

Displaying 581 - 600 of 1001 results.

Pages

At the request of Governor Sarah Palin and the Alaska Department of Health and Social Services, the Federal Trade Commission has submitted written testimony to the Standing Committee on Health, Education, and Social Services of the state’s House of Representatives concerning health care...
Commission approval of staff comments: At his request, staff of the FTC’s Office of Policy Planning, Bureau of Competition, and Bureau of Economics have submitted comments to Ohio State Senator William J.
Staff advisory opinion concerning Non-Profit Institutions Act: The staff of the Bureau of Competition has advised Kaiser Foundation Health Plan, Inc. that, in the staff’s opinion, Kaiser’s purchase and use of discounted pharmaceuticals in connection with a proposed program to provide health care...
The Federal Trade Commission today filed a complaint in federal district court against Cephalon, Inc., a pharmaceutical company based in Frazer, Pennsylvania, for a course of anticompetitive conduct that is preventing competition to its branded drug Provigil. The conduct includes paying four firms...
On 2/13/2008, the Commission filed a complaint in federal district court charging Cephalon, Inc. with preventing competition to its branded drug Provigil. The conduct under challenge includes paying four firms to refrain from selling generic versions of Provigil until 2012. Cephalon’...
Commission approval of staff comments: The FTC’s Office of Policy Planning, Bureau of Competition, and Bureau of Economics have submitted comments to Antonio Silva Delgado of the Treasury and Financial Affairs Commission of the Puerto Rico House of Representatives regarding Senate Bill (S.B.) 2190...
Amicus brief before the United States Court of Appeals for the Federal Circuit, in support of appellants and urging reversal of a decision by the United States District Court for the Eastern District of New York dismissing plaintiffs-appellants' federal antitrust claims on the ground...
Commission issuance of information requests: The Commission has issued information requests to generic and authorized generic drug manufacturers and marketers as part of its ongoing study of the short- and long-term effects of authorized generics on pharmaceutical drug competition. The current set...
Two marketers of non-corrective, cosmetic contact lenses have agreed to settle Federal Trade Commission charges that they violated federal law by selling lenses without prescriptions.
The Federal Trade Commission today announced a complaint challenging Schering-Plough Corporation’s proposed $14.4 billion acquisition of Organon BioSciences N.V. from Akzo-Nobel N.V., alleging that the deal would harm competition in the U.S. markets for the manufacture and development of three...
Commission approval of amended complaint filing: The Commission has approved the filing of an amended complaint in the matter currently pending against Direct Marketing Concepts, Inc., et al. The original complaint in this case, announced earlier this month, charged the marketers of Kevin Trudeau’...
Providing Federal Trade Commission testimony today before the Antitrust Task Force of the U.S. House of Representatives’ Committee on the Judiciary, Deputy Bureau of Competition Director David P. Wales, Jr., presented the Commission’s views on H.R. 971, the Community Pharmacy Fairness Act of 2007...
On October 12, Federal Trade Commission staff sent warning letters to 15 sellers of non-corrective, cosmetic contact lenses who appeared to be providing contact lenses to consumers without valid prescriptions. Under the FTC’s Contact Lens Rule, sellers of both corrective and non-corrective...
The Commission challenged Kyphon Inc.’s $220 million proposed acquisition of the spinal assets of Disc-O-Tech Medical Technologies, Ltd. and Discotech Orthopedic Technologies (collectively Disc-O-Tech) as anticompetitive in the market for minimally invasive vertebral compression...
The Federal Trade Commission today announced a complaint challenging Kyphon, Inc.’s (Kyphon) proposed acquisition of the spinal assets of Disc-O-Tech Medical Technologies, Ltd. and Discotech Orthopedic Technologies, Inc. (collectively Disc-O-Tech) as anticompetitive in the U.S. market for...
Commission approval of filing of staff comments: The Commission has approved the filing of comments by the staff of the Office of Policy Planning and the Bureaus of Economics, Competition, and Consumer Protection with the Massachusetts Department of Public Health (DPH) regarding proposed limited...
The Federal Trade Commission today announced its challenge of Mylan Laboratories’ (Mylan) proposed $6.6 billion acquisition of Germany’s E. Merck oHG (Merck), alleging that the transaction would result in significantly reduced competition for the sale and manufacture of five generic drugs in the U...
The Commission ordered divestitures to resolve competitive concerns in the U.S. market for five generic drugs stemming from Mylan Laboratories’ proposed acquisition of the generic arm of Merck Pharmaceuticals, a transaction valued at approximately $6.6 billion. Under a September 2007...
Staff of the Federal Trade Commission have advised the Greater Rochester Independent Practice Association, Inc. (GRIPA), a multi-specialty physician practice association that includes competing primary care and specialist physicians that practice in the three-county greater Rochester, New York,...
Commission approval of final consent orders: The Commission has approved a final consent order in the matter concerning the South Carolina State Board of Dentistry and approved letters to the commenters of record. The FTC vote approving the final consent order was 5-0. (FTC Docket No. D-9311; the...

Pages